Alliances
Two years after forging a partnership to collaborate on microbiome targets for gastrointestinal disorders, France-based Enterome SA and Takeda Pharmaceuticals have entered into a second agreement. This time with a specific focus on Crohn’s disease.
Arjo today signed an agreement to divest Acare – the group’s low-spec medical beds business – to China-based CBL Group. The divestment is a key part of the group’s action plan to improve profitability in the medical beds product category.
Mymetics Corporation announced today that Mymetics BV, the Dutch subsidiary of Mymetics Corporation, has entered into a research collaboration project with eTheRNA immunotherapies NV, a clinical stage biotech company developing novel mRNA cancer immunotherapies.
Timicoin/TimiHealth announced a joint partnership with US HealthCenter and PredictiMed that is designed to focus on the capabilities of a blockchain tokenized hybrid rewards program.
Distributor will supply Chirascan circular dichroism spectrometers and SX stopped-flow spectrometers to Ireland and Northern Ireland
Hemogenyx Pharmaceuticals Plc announces that its wholly owned subsidiary, Immugenyx, LLC (“Immugenyx”), has entered into a collaboration agreement with Janssen Research & Development, LLC (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation LLC.
Weeks after Waltham, Mass.-based Morphic Therapeutic secured $80 million in Series B financing that was supported in part by AbbVie Ventures, the company struck a deal with the pharma giant to collaborate on the development of therapies for fibrosis-related indications.
First public trial of DnaNudge’s technology has today been launched to study effects of DNA-based food choices for pre-diabetic individuals
Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.
Again and again … and again, drugs have failed in clinical trials for Alzheimer’s disease. According to a new report, in the last decade, 146 drugs have failed in clinical trials for Alzheimer’s.
PRESS RELEASES